Independent Scientist, Wellington, 6037, New Zealand.
Comput Biol Med. 2024 Nov;182:109137. doi: 10.1016/j.compbiomed.2024.109137. Epub 2024 Sep 10.
This narrative review examines the promising potential of integrating artificial intelligence (AI) with CRISPR-Cas9 genome editing to advance CAR T-cell therapy. AI algorithms offer unparalleled precision in identifying genetic targets, essential for enhancing the therapeutic efficacy of CAR T-cell treatments. This precision is critical for eliminating negative regulatory elements that undermine therapy effectiveness. Additionally, AI streamlines the manufacturing process, significantly reducing costs and increasing accessibility, thereby encouraging further research and development investment. A key benefit of AI integration is improved safety; by predicting and minimizing off-target effects, AI enhances the specificity of CRISPR-Cas9 edits, contributing to safer CAR T-cell therapy. This advancement is crucial for patient safety and broader clinical adoption. The convergence of AI and CRISPR-Cas9 has transformative potential, poised to revolutionize personalized immunotherapy. These innovations could expand the application of CAR T-cell therapy beyond hematologic malignancies to various solid tumors and other non-hematologic conditions, heralding a new era in cancer treatment that substantially improves patient outcomes.
这篇综述探讨了将人工智能（AI）与 CRISPR-Cas9 基因组编辑相结合，以推进 CAR T 细胞疗法的有前途的潜力。人工智能算法在识别遗传靶标方面提供了无与伦比的精度，这对于增强 CAR T 细胞治疗的疗效至关重要。这种精度对于消除削弱治疗效果的负调节元件至关重要。此外，人工智能简化了制造过程，显著降低了成本并提高了可及性，从而鼓励进一步的研究和开发投资。人工智能集成的一个关键好处是提高了安全性；通过预测和最小化脱靶效应，人工智能提高了 CRISPR-Cas9 编辑的特异性，有助于更安全的 CAR T 细胞治疗。这一进展对于患者安全和更广泛的临床应用至关重要。人工智能和 CRISPR-Cas9 的融合具有变革性的潜力，有望彻底改变个性化免疫疗法。这些创新可以将 CAR T 细胞疗法的应用扩展到血液恶性肿瘤以外的各种实体瘤和其他非血液疾病，开创癌症治疗的新时代，极大地改善患者的治疗效果。
